Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Bioorg Med Chem Lett ; 30(23): 127560, 2020 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-32956781

RESUMO

The NLRP3 inflammasome is a component of the innate immune system involved in the production of proinflammatory cytokines. Aberrant activation by a wide range of exogenous and endogenous signals can lead to chronic, low-grade inflammation. It has attracted a great deal of interest as a drug target due to the association with diseases of large unmet medical need such as Alzheimer's disease, Parkinson's disease, arthritis, and cancer. To date, no drugs specifically targeting inhibition of the NLRP3 inflammasome have been approved. In this work, we used the known NLRP3 inflammasome inhibitor CP-456,773 (aka CRID3 or MCC 950) as our starting point and undertook a Structure-Activity Relationship (SAR) analysis and subsequent scaffold-hopping exercise. This resulted in the rational design of a series of novel ester-substituted urea compounds that are highly potent and selective NLRP3 inflammasome inhibitors, as exemplified by compounds 44 and 45. It is hypothesized that the ester moiety acts as a highly permeable delivery vehicle and is subsequently hydrolyzed to the carboxylic acid active species by carboxylesterase enzymes. These molecules are greatly differentiated from the state-of-the-art and offer potential in the treatment of NLRP3-driven diseases, particularly where tissue penetration is required.


Assuntos
Ésteres/farmacologia , Indenos/farmacologia , Inflamassomos/antagonistas & inibidores , Proteína 3 que Contém Domínio de Pirina da Família NLR/antagonistas & inibidores , Ureia/análogos & derivados , Ureia/farmacologia , Animais , Sangue/metabolismo , Desenho de Fármacos , Estabilidade de Medicamentos , Ésteres/síntese química , Ésteres/metabolismo , Furanos , Compostos Heterocíclicos de 4 ou mais Anéis/química , Humanos , Indenos/síntese química , Indenos/metabolismo , Camundongos , Estrutura Molecular , Relação Estrutura-Atividade , Sulfonamidas , Sulfonas/química , Células THP-1
2.
Bioorg Med Chem Lett ; 28(4): 618-625, 2018 02 15.
Artigo em Inglês | MEDLINE | ID: mdl-29395971

RESUMO

A series of optically pure (R)- and (S)-1,3,4,12a-tetrahydropyrazino[2,1-c][1,4]benzodiazepine-6,12(2H,11H)-dione derivatives was designed and synthesized as novel anthramycin analogues in a three-step, one-pot procedure, and tested for their antiproliferative activity on nine following cell lines: MV-4-11, UMUC-3, MDA-MB-231, MCF7, LoVo, HT-29, A-549, A2780 and BALB/3T3. The key structural features responsible for exhibition of cytotoxic effect were determined: the (S)-configuration of chiral center and the presence of hydrophobic 4-biphenyl substituent in the side chain. Introduction of bromine atom into the 8 position (8g) or substitution of dilactam ring with benzyl group (8m) further improved the activity and selectivity of investigated compounds. Among others, compound 8g exhibited selective cytotoxic effect against MV-4-11 (IC50 = 8.7 µM) and HT-29 (IC50 = 17.8 µM) cell lines, while 8m showed noticeable anticancer activity against MV-4-11 (IC50 = 10.8 µM) and LoVo (IC50 = 11.0 µM) cell lines. The cell cycle arrest in G1/S checkpoint and apoptosis associated with overproduction of reactive oxygen species was also observed for 8e and 8m.


Assuntos
Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Benzodiazepinonas/farmacologia , Pirazinas/farmacologia , Espécies Reativas de Oxigênio/metabolismo , Animais , Antineoplásicos/síntese química , Antineoplásicos/química , Antineoplásicos/toxicidade , Benzodiazepinonas/síntese química , Benzodiazepinonas/química , Benzodiazepinonas/toxicidade , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Relação Dose-Resposta a Droga , Ensaios de Seleção de Medicamentos Antitumorais , Pontos de Checagem da Fase G1 do Ciclo Celular/efeitos dos fármacos , Humanos , Leucemia/tratamento farmacológico , Camundongos , Pirazinas/síntese química , Pirazinas/química , Pirazinas/toxicidade , Pontos de Checagem da Fase S do Ciclo Celular/efeitos dos fármacos , Estereoisomerismo , Relação Estrutura-Atividade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA